Document is current
Any future updates will be listed below
-
Authors
Arumuham, Atheeshaan https://orcid.org/0000-0001-9018-0305
Shatalina, Ekaterina
Nour, Matthew M.
Veronese, Mattia
Onwordi, Ellis Chika
Kaar, Stephen J.
Jauhar, Sameer
Rabiner, Eugenii A.
Howes, Oliver D.
-
Funding
Funding for this research was provided by:
Medical Research Council (MC_A656_5QD30_2135)
Maudsley Charity (666)
Wellcome Trust (094849/Z/10/Z)
- License Information
-
More Information
Article History
Received: 25 August 2024
Accepted: 27 November 2024
First Online: 22 December 2024
Declarations
:
: AA, ES, MMN, SJK, MV, and ECO have no conflicting interests to declare. In the last 3 years, SJ has given non-promotional educational talks for Lundbeck, Janssen, and Sunovion. EAR is a full-time employee of Invicro, an imaging centre conducting contract studies for pharmaceutical and biotech partners. As part of his role, EAR has consulted for numerous industry and academic entities. ODH is a part-time employee and stockholder of Lundbeck A/s. He has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche and Viatris/ Mylan. ODH has a patent for the use of dopaminergic imaging.
